AstraZeneca
The latest news about AstraZeneca: headlines, AI summaries and the full story from every source.
- AstraZeneca's Breast Cancer Drug Fails Late-Stage Trial, Citi Maintains 'Buy' Rating
- Positive Lung Cancer Trial Results for Amgen's Imdelltra and AstraZeneca's Imfinzi
- Deutsche Bank Maintains 'Sell' Rating on AstraZeneca Despite Positive Drug Data
- AstraZeneca's COPD Drug Shows Strong Trial Results and Blockbuster Potential
- AstraZeneca Considering $400 Billion Merger with Bristol Myers Squibb
- AstraZeneca's Drug Pipeline Divides City Analysts
- AstraZeneca PLC Announces Interim Dividend of $1.06 Per Share
- AstraZeneca Faces Rare Test After Trial Failure and Share Price Drop
- AstraZeneca Shares Decline After HSBC Downgrades Rating Due to Wainua Trial Setback
- UBS Maintains Positive Outlook on AstraZeneca Ahead of Q2 Earnings
- AstraZeneca Shares Drop After Heart Disease Drug Fails Clinical Trial
- Jefferies Warns AstraZeneca's Wainua Trial Failure Damages Credibility More Than Valuation
- AstraZeneca's CARES Phase III Clinical Programme Fails to Meet Primary Endpoint
- AstraZeneca Receives FDA AdCom Recommendation for Truqap in Prostate Cancer Treatment
- AstraZeneca's Cancer Drug Faces FDA Advisory Panel Rejection
- Citi Raises AstraZeneca Earnings Forecast and Maintains 'Buy' Rating Ahead of Second-Half Pipeline Catalysts
- AstraZeneca's Breztri Approved in the U.S. for Asthma Treatment
- AstraZeneca Announces Positive Interim Results for Ultomiris in I CAN Phase III Trial